Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
445 Results for "
localize
" in MedChemExpress (MCE) Product Catalog:
Products (445)
445 Results for "localize" in MCE Product Catalog:
Cat. No.: HY-156675
CAS No.: 2119725-22-1
Target:
Microtubule/Tubulin Eukaryotic Initiation Factor (eIF) HSP Caspase Reactive Oxygen Species (ROS) Apoptosis
Research Areas:
Plecstatin‑1 is a metal complex that drives the aggregation and collapse of the plectin network, and disrupts the cytoskeletal structures of α‑tubulin and F‑actin. Plecstatin-1 triggers oxidative stress, mediates the phosphorylation of eIF2α, and induces molecular features associated with immunogenic cell death, including calreticulin membrane exposure, membrane localization of HSP70/HSP90, ATP secretion, and HMGB‑1 release. Plecstatin-1 induces apoptosis via the intrinsic mitochondrial pathway and exerts anti-invasive activity. Plecstatin‑1 inhibits sphere proliferation and reduces clonogenicity in the 3D tumor spheroid model of colon cancer cells. Plecstatin-1 is applicable to relevant research on colorectal cancer .
Cat. No.: HY-158726
CAS No.: 2480150-28-3
Cat. No.: HY-165426
CAS No.: 3031522-14-9
Target:
Research Areas:
HB-230 is a Transglutaminase-2 (TG2) (human IC50 = 4.9 μM) inhibitor and a selective fluorescent imaging probe for active TG2 localization. HB-230 modifies TG2 Cys277 to sustain the enzyme open conformation. HB-230 forms a ternary complex with TG2 and α2-macroglobulin, undergoes receptor-mediated endocytosis, and trafficks directly to lysosomes without early/late endosome fusion. HB-230 exhibits TG2 activity-dependent and α2-macroglobulin-dependent uptake. HB-230 can be used for the research of celiac disease, (Ex/Em = 649/665 nm) .
Cat. No.: HY-174499
Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
Cat. No.: HY-175496
CAS No.: 2907705-12-6
Target:
Research Areas:
Acid Ceramidase-IN-3 is a acid ceramidase (aCDase) inhibitor. Acid Ceramidase-IN-3 inhibits the enzymatic activity of aCDase with a pIC 50 of 8.5 in enzymatic assays and 6.8 in A375 melanoma cellular assays. Acid Ceramidase-IN-3 promotes HSC inactivation, as measured by a dose-dependent
reduction in COL1A1 and ACTA2. Acid Ceramidase-IN-3 inhibits aCDase activity in HSCs, promotes HSC inactivation and suppresses YAP/TAZ nuclear localization. Acid Ceramidase-IN-3 increases Dynein/Kinesin (NDE1, NDEL1.
KIF3B, KIF15) while decreases several proteins involved with signaling pathway (SARM1, RGAP1,
PDGF-D,PDGFR-B). Acid Ceramidase-IN-3 can be used for the study of fibrotic diseases .
Cat. No.: HY-403733B
CAS No.: 1998094-24-8
Research Areas:
(+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 (HY-403733A) in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100) (HY-70003) .
Research Areas:
Succinylsulfathiazole (Standard) (Succinylsulphathiazole) is the analytical standard of Succinylsulfathiazole (HY-B0921). This product is intended for research and analytical applications. Succinylsulfathiazole is a long-acting sulfonamide antibiotic with localized gut-specific antibacterial activity and is orally active. Succinylsulfathiazole inhibits bacterial folate synthesis, reduces coliform counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes gut folate-producing bacteria. Succinylsulfathiazole modulates hepatic mTOR signaling, diminishes cecal fermentation, decreases hepatic folate levels and total folate excretion, elevates nitrogen excretion and reduces the fermentability of certain dietary fibers. Succinylsulfathiazole induces folate deficiency and triggers biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice .
Cat. No.: HY-D0074
CAS No.: 70504-01-7
Target:
Research Areas:
Prodan is an environment-sensitive fluorescent probe used to investigate the polarity, fluidity, and structure of lipid membranes. Prodan exhibits environment-dependent excitation/emission wavelengths, with its wavelength range covering Ex = 360-410 nm and Em = 430-530 nm when in solvents, bound to DNA, located in lipid bilayers, or associated with proteins. Prodan can interact with the major groove of DNA, regions of lipid bilayers, and hydrophobic pockets of proteins. During phase transitions, Prodan localizes to different regions of the bilayer: the emission minimum is 430-440 nm in the gel phase, while it shifts to 480-500 nm in the liquid-crystalline phase or interdigitated gel phase. When bound to rigid hydrophobic sites of proteins, the emission peak of Prodan undergoes a blue shift and its fluorescence intensity increases .
Cat. No.: HY-D3197
Cat. No.: HY-D3198
CAS No.: 2351937-34-1
Target:
Research Areas:
NIR-fluorescent ceramide is a neutral near-infrared (NIF) fluorescent probe (λem=650 nm) based on the C-bridged nitrobenzoxadiazole SCOTfluor core, which enables visualization of lipid metabolic processes such as sphingolipid trafficking. The emission signal of NIR-fluorescent ceramide increases significantly in liposomal environments. NIR-fluorescent ceramide acts as an intracellular trafficking tracer, localizing to regions surrounding the endoplasmic reticulum and Golgi apparatus within a short period, and then translocating to recycling lysosomes over a longer period, thus enabling real-time visualization of sphingolipid trafficking and biological lipid functions in living cells. NIR-fluorescent ceramide also generates metabolic uptake profiles and provides multiple metabolic readouts in human cancer cell lines .
Cat. No.: HY-D3389
Cat. No.: HY-P11231
CAS No.: 2780353-11-7
Synonyms: FUS(364-369)-TAT
Target:
Research Areas:
Cat. No.: HY-P4121
CAS No.: 1898254-09-5
Target:
Research Areas:
Cat. No.: HY-P991029
CAS No.: 2933972-64-4
Synonyms: HMB-001
Target:
Research Areas:
Cat. No.: HY-L147
956 compounds
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. Proteases play important roles in regulating multiple biological processes in all living organisms, such as regulating the fate, localization, and activity of many proteins, modulating protein-protein interactions, creating new bioactive molecules, contributing to the processing of cellular information, and generating, transducing, and amplifying molecular signals.
Proteases are important targets in drug discovery. Some protease inhibitors are often used as anti-virus drugs and anti-cancer drugs. MCE offers a unique collection of 956 protease inhibitors. MCE Protease Inhibitor Library is critical for drug discovery and development.
Cat. No.: HY-118506
CAS No.: 612046-20-5
Target:
Research Areas:
BRP-7 is a 5-lipoxygenase activating protein (FLAP) inhibitor with an IC50 of 0.31 μM. BRP-7 inhibits the co-localization of 5-lipoxygenase (5-LOX) and FLAP by targeting FLAP, thereby blocking the transfer of arachidonic acid (AA) to 5-LOX and suppressing the production of leukotrienes (LTs) (IC₅₀ = 0.15 μM). BRP-7 does not inhibit cyclooxygenase (COX-1/COX-2) or microsomal prostaglandin E₂ synthase-1 (mPGES-1), and does not affect cell viability or AA release. BRP-7 exhibits significant anti-inflammatory effects in rat pleurisy and mouse peritonitis models. BRP-7 can be used for the study of inflammatory diseases .
Cat. No.: HY-138660
CAS No.: 2376841-30-2
Synonyms: HM-JF526 NHS
Target:
Research Areas:
HM Janelia Fluor 526, SE (HM-JF526 NHS) is a derivative of hydroxymethyl JF526 (HM-JF526). SMLM (single-molecule localization microscopy) imaging in standard phosphate-buffered saline (pH 7.4) revealed that the HM-JF526 label showed spontaneous blinking behavior throughout the imaging session and did not require short-wavelength activation light . Janelia Fluor fluorescent dyes can be chemically conjugated to the specific HaloTag substrate (a chloroalkane ligand) to form a fluorescent ligand, rather than binding directly to the HaloTag protein itself. Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
Synonyms: N-Behenoyl-D-erythro-sphingosine; C22-Ceramide; Cer d18:1/22:0
Target:
Research Areas:
C22-Ceramide (d18:1/22:0) (N-Behenoyl-D-erythro-sphingosine) is an ultra-long-chain ceramide containing a C22:0 behenoyl acyl chain. C22-Ceramide can be glycosylated via CGT-3 to form C22 glucosylceramide (C22 GlcCer), which in turn maintains clathrin membrane localization and lysosomal homeostasis, inhibits TOR signaling and promotes SKN-1 activation, thereby enhancing oxidative stress resistance and extending the lifespan of C. elegans. C22-Ceramide can be used in research on cardiometabolic diseases such as type 2 diabetes, obesity, dyslipidemia, coronary artery disease and thin-cap fibroatheroma (TCFA), as well as oxidative stress and aging-related studies .
Cat. No.: HY-182383
CAS No.: 1209002-42-5
VMY-1-101 is a fluorescent cyclin-dependent kinase (CDK) inhibitor, with an excitation of 410 nm and emission of 512 nm. VMY-1-101 competitively inhibits ATP binding to CDKs. VMY-1-101 induces G2/M cell cycle arrest in human breast cancer cells. VMY-1-101 induces modest apoptosis in human breast cancer cells. VMY-1-101 blocks proliferation of human breast cancer cells, including multidrug resistance-positive cells, and is not a substrate for p-glycoprotein. VMY-1-101 localizes to the cytoplasm of human breast cancer cells. VMY-1-101 shows increased binding to human breast cancer tissue compared to fluorophore alone. VMY-1-101 can be used for the research of breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
